Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:f4e0e1bddd3d9d8b40b17cc2f9827c1f]
Median time to PSA progression will be determined as a function of the date the patient started on androgen deprivation and as a function of treatment start date (week 0). Development of new metastases or discontinuation of study to begin other therapy, while not expected to precede a PSA progression endpoint, would also constitute a progression endpoint.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:f4e0e1bddd3d9d8b40b17cc2f9827c1f]
Median time to PSA progression will be determined as a function of the date the patient started on androgen deprivation and as a function of treatment start date (week 0). Development of new metastases or discontinuation of study to begin other therapy, while not expected to precede a PSA progression endpoint, would also constitute a progression endpoint.
Bio2RDF identifier
f4e0e1bddd3d9d8b40b17cc2f9827c1f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f4e0e1bddd3d9d8b40b17cc2f9827c1f
measure [clinicaltrials_vocabulary:measure]
Number and severity of adverse ...... ith metastatic prostate cancer
time frame [clinicaltrials_vocabulary:time-frame]
From first immunization to Week 72
description
Median time to PSA progression ...... titute a progression endpoint.
identifier
clinicaltrials_resource:f4e0e1bddd3d9d8b40b17cc2f9827c1f
title
Number and severity of adverse ...... first immunization to Week 72
@en
type
label
Number and severity of adverse ...... 0e1bddd3d9d8b40b17cc2f9827c1f]
@en